|Day's Range||0.1800 - 0.1800|
QIAGEN builds on global collaboration with Amgen for companion diagnostic development in non-small cell lung cancer
Calibre Scientific is pleased to announce that it has completed the acquisition of the NeXtal Biotechnologies line of structural biology products from Qiagen NV (QGEN). NeXtal specializes in the production of unique screens and plates for protein crystallization, an important step in the complex process of structural biology studies and structure-based drug design. NeXtal’s products include a comprehensive suite of reliable crystallization screens and proprietary EasyXtal crystallization plates that are currently sold into academic, biotechnology, and pharmaceutical markets.
Benzinga's PreMarket Prep show resumed Thursday after a pause for the Christmas holiday. As always, there were a few market movers to cover and two informative interviews. Qiagen Decides Not To Sell When ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...
Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business. Qiagen announced last month that it had received "several" entreaties to acquire the molecular-diagnostics specialist, and were exploring the opportunities. Shares, which had been hit hard by a CEO departure and China-related concerns, rebounded on that news. After the shortened Christmas Eve trading session ended, though, Qiagen announced that its management and supervisory boards had opted against a sale and terminated all discussions because "the alternatives to the stand-alone business plan prospects were not compelling." Shares closed Tuesday with a 0.8% increase at $41.47, then dove to less than $31 in after-hours trading following the announcement.
QIAGEN concludes strategic alternatives review; decides to focus on stand-alone business strategy to drive future value creation
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
QIAGEN and DiaSorin receive FDA approval for the LIAISON QuantiFERON-TB Gold Plus Test on LIAISON platforms and begin commercial launch
NEW YORK, Nov. 25, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V..
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
Seven-year collaboration expands LabCorp’s use of QIAGEN’s QCI platform with QIAGEN’s Human Gene Mutation Database for rare and hereditary workflows
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.